Drug Approval | March 21, 2022
USFDA approves Perrigo’s Nasonex
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
DASH enables non-laboratory personnel to insert a nasal swab specimen directly into our test cartridge and then load the cartridge into the DASH instrument, providing an accurate result in about 15 minutes
Clinical surveillance solution is designed to identify emergent patient deterioration and offer enhanced patient data visibility, flexible viewing options, and clinical decision support
This is the sixth successful USFDA audit for this facility
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
It is only the second generic application approved by the USFDA
Subscribe To Our Newsletter & Stay Updated
